[Interleukin-6 in pathogenesis of rheumatoid arthritis].
Mihara
Masahiko
M
Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd.
Nishimoto
Norihiro
N
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000502:physiology; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000209:etiology*; D001323:Autoantibodies; D001402:B-Lymphocytes / Q000276:immunology; D002454:Cell Differentiation; D003094:Collagen / Q000378:metabolism; D050822:Cytokine Receptor gp130; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D018836:Inflammation Mediators; D015850:Interleukin-6 / Q000276:immunology / Q000502:physiology*; D008562:Membrane Glycoproteins / Q000502:physiology; D010010:Osteoclasts / Q000166:cytology; D019947:Receptors, Interleukin-6 / Q000235:genetics / Q000502:physiology; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018501:Antirheumatic Agents; D001323:Autoantibodies; C494199:IL6ST protein, human; D018836:Inflammation Mediators; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130; D003094:Collagen